Drug Trial Radar · NCT01306786
Five Days Quadruple and Clarithromycin Containing Triple Therapy as Treatment for Helicobacter Pylori Eradication
Last checked: Nov 19, 2026Latest source record: May 28, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
800
Actual
Start
Nov 2008
Primary completion
Oct 2010
Study completion Feb 2011
Sponsor
- Lead sponsor
- The University of Hong KongAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Mar 2, 2011
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 21 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of this randomized trial is to compare the efficacy and tolerability of H. pylori eradication with a 5-day quadruple therapy versus a clarithromycin-containing triple therapy.
Conditions
- Helicobacter Pylori Infection
Interventions
Quadruple therapyDrug
First line: 5 days esomeprazole 20mg b.d., bismuth subcitrate 120mg q.i.d., tetracycline 250mg q.i.d. and metronidazole 250mg q.i.d. Cross over second line for those who failed first line: 7 days esomeprazole 20mg b.d., amoxicillin 1g b.d. and clarithromycin 500mg b.d
Triple therapyDrug
First line: 7 days esomeprazole 20mg b.d., amoxicillin 1g b.d. and clarithromycin 500mg b.d Second line cross over if failed first line: 7 days quadruple therapy: esomeprazole 20mg b.d., bismuth subcitrate 120mg q.i.d., tetracycline 250mg q.i.d. and metronidazole 250mg q.i.d.)
Primary outcomes
What the sponsor says the trial is designed to measure.
- H pylori eradicationTime frame: 8 weeks after treatment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The University of Hong Kong, Queen Mary Hospital
Hong Kong SAR, Hong Kong
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.